43.43
price down icon0.34%   -0.15
after-market Handel nachbörslich: 43.25 -0.18 -0.41%
loading
Schlusskurs vom Vortag:
$43.58
Offen:
$42.87
24-Stunden-Volumen:
621.70K
Relative Volume:
0.76
Marktkapitalisierung:
$4.00B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-6.7125
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
-4.28%
1M Leistung:
+3.23%
6M Leistung:
-14.68%
1J Leistung:
-7.08%
1-Tages-Spanne:
Value
$42.52
$43.74
1-Wochen-Bereich:
Value
$42.52
$46.50
52-Wochen-Spanne:
Value
$37.02
$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name
Firmenname
Ultragenyx Pharmaceutical Inc
Name
Telefon
415-483-8800
Name
Adresse
60 LEVERONI COURT, NOVATO, CA
Name
Mitarbeiter
1,276
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
RARE's Discussions on Twitter

Vergleichen Sie RARE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
43.43 4.00B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
453.20 116.71B 11.02B -535.60M -1.35B -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
663.86 72.58B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
649.09 39.44B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
265.96 34.30B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
111.89 26.82B 3.30B -501.07M 1.03B -2.1146

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-06-06 Hochstufung Goldman Neutral → Buy
2024-04-22 Eingeleitet RBC Capital Mkts Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-06-06 Hochstufung Evercore ISI In-line → Outperform
2023-04-26 Eingeleitet Cantor Fitzgerald Overweight
2023-01-18 Fortgesetzt Canaccord Genuity Buy
2022-12-30 Fortgesetzt H.C. Wainwright Buy
2022-11-03 Hochstufung Robert W. Baird Neutral → Outperform
2022-10-13 Hochstufung Guggenheim Neutral → Buy
2022-08-01 Herabstufung Evercore ISI Outperform → In-line
2022-03-16 Hochstufung Credit Suisse Neutral → Outperform
2022-02-11 Hochstufung JP Morgan Neutral → Overweight
2021-09-30 Eingeleitet H.C. Wainwright Buy
2021-08-19 Eingeleitet UBS Sell
2021-07-15 Eingeleitet Guggenheim Neutral
2021-06-29 Hochstufung BofA Securities Neutral → Buy
2021-06-04 Fortgesetzt Robert W. Baird Neutral
2021-05-06 Hochstufung Citigroup Neutral → Buy
2021-05-06 Hochstufung Evercore ISI In-line → Outperform
2021-04-26 Fortgesetzt Credit Suisse Neutral
2021-03-02 Fortgesetzt Stifel Buy
2021-02-12 Herabstufung JP Morgan Overweight → Neutral
2020-12-07 Herabstufung Wedbush Outperform → Neutral
2020-11-24 Fortgesetzt Evercore ISI In-line
2020-11-12 Herabstufung BofA Securities Buy → Neutral
2019-08-02 Fortgesetzt Wedbush Outperform
2019-03-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-02-22 Fortgesetzt Raymond James Outperform
2019-01-02 Herabstufung Raymond James Outperform → Mkt Perform
2018-11-08 Hochstufung Citigroup Sell → Neutral
2018-09-10 Eingeleitet Morgan Stanley Equal-Weight
2018-06-21 Herabstufung Credit Suisse Outperform → Neutral
2018-05-11 Hochstufung Barclays Equal Weight → Overweight
2018-05-10 Eingeleitet Goldman Neutral
2018-04-18 Hochstufung SunTrust Hold → Buy
2018-03-22 Fortgesetzt Piper Jaffray Overweight
2018-02-21 Bestätigt Stifel Buy
2018-01-22 Hochstufung Evercore ISI In-line → Outperform
2018-01-18 Eingeleitet Credit Suisse Outperform
2017-12-05 Bestätigt Barclays Equal Weight
2017-12-04 Hochstufung Jefferies Hold → Buy
2017-09-14 Hochstufung Wedbush Neutral → Outperform
Alle ansehen

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
Feb 12, 2025

Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Feb 12, 2025
pulisher
Feb 11, 2025

WCM Investment Management LLC Has $5.73 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by abrdn plc - MarketBeat

Feb 11, 2025
pulisher
Feb 08, 2025

RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study - MSN

Feb 08, 2025
pulisher
Feb 07, 2025

Ultragenyx Pharmaceuticals: Buy Rating Supported by Promising Gene Therapy Trial Results and Regulatory Advancements - TipRanks

Feb 07, 2025
pulisher
Feb 07, 2025

Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $92.43 - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update - GlobeNewswire

Feb 06, 2025
pulisher
Feb 06, 2025

Rare Disease Leader Ultragenyx to Reveal Full Year Performance: Key Earnings Date Announced - StockTitan

Feb 06, 2025
pulisher
Feb 06, 2025

UX111 offers cognitive, motor skill gains in Sanfilippo syndrome type A - Sanfilippo News

Feb 06, 2025
pulisher
Feb 06, 2025

Rett Syndrome Market Growth Projections 2024-2034: - openPR

Feb 06, 2025
pulisher
Feb 06, 2025

Adicet's T-Cell Therapy ADI-100 Fast Tracked by FDA for Refractory Systemic Lupus Erythematosus - CGTLive™

Feb 06, 2025
pulisher
Feb 06, 2025

Ultragenyx announces new data on UX111 AV gene therapy - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

Ultragenyx updates on UX111 AAV gene therapy - The Pharma Letter

Feb 06, 2025
pulisher
Feb 05, 2025

Ultragenyx links cognitive improvement to biomarker in latest Sanfilippo gene therapy readout - FirstWord Pharma

Feb 05, 2025
pulisher
Feb 05, 2025

Ultragenyx Announces New Data Demonstrating that Treatment - GlobeNewswire

Feb 05, 2025
pulisher
Feb 05, 2025

Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2 - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Ultragenyx reports positive data on gene therapy for rare disease - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Ultragenyx reports positive data on gene therapy for rare disease By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Breakthrough: Ultragenyx's Gene Therapy Reverses Cognitive Decline in Fatal Childhood Disease - StockTitan

Feb 05, 2025
pulisher
Feb 05, 2025

KBC Group NV Buys 58,442 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Feb 05, 2025
pulisher
Jan 30, 2025

Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart

Jan 30, 2025
pulisher
Jan 29, 2025

Ultragenyx Pharmaceutical: Advancing On Multiple Fronts (NASDAQ:RARE) - Seeking Alpha

Jan 29, 2025
pulisher
Jan 28, 2025

Wilson’s Disease Market Expected to rise, 2034 | Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, expected to drive market - Barchart

Jan 28, 2025
pulisher
Jan 28, 2025

Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications - CGTLive™

Jan 28, 2025
pulisher
Jan 28, 2025

Learn to Evaluate (RARE) using the Charts - Stock Traders Daily

Jan 28, 2025
pulisher
Jan 27, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) adds US$374m to market cap in the past 7 days, though investors from three years ago are still down 37% - Simply Wall St

Jan 27, 2025
pulisher
Jan 27, 2025

What is Wedbush’s Estimate for RARE FY2024 Earnings? - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Wedbush Has Positive Outlook for RARE FY2027 Earnings - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Wedbush Equities Analysts Boost Earnings Estimates for RARE - MarketBeat

Jan 24, 2025
pulisher
Jan 23, 2025

Ultragenyx's SWOT analysis: rare disease stock poised for growth - Investing.com India

Jan 23, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Forecasts RARE FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 23, 2025

FY2024 Earnings Estimate for RARE Issued By Leerink Partnrs - Defense World

Jan 23, 2025
pulisher
Jan 23, 2025

Mucopolysaccharidosis (MPS) Treatment Market Growth in Future - openPR

Jan 23, 2025
pulisher
Jan 22, 2025

Ultragenyx's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Australia

Jan 22, 2025
pulisher
Jan 22, 2025

Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views - Benzinga

Jan 22, 2025
pulisher
Jan 22, 2025

Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Leerink Partnrs Has Positive Outlook of RARE FY2024 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Cantor Fitzgerald Predicts RARE FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Sells 76,160 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Jan 22, 2025
pulisher
Jan 18, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 18, 2025
pulisher
Jan 18, 2025

FY2024 EPS Estimates for RARE Boosted by Cantor Fitzgerald - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7%Should You Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential - Insider Monkey

Jan 17, 2025
pulisher
Jan 17, 2025

12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey

Jan 17, 2025

Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$32.34
price up icon 0.28%
$19.57
price up icon 2.57%
$4.63
price up icon 3.58%
$370.74
price up icon 4.93%
biotechnology ONC
$223.31
price up icon 0.94%
$111.89
price down icon 2.28%
Kapitalisierung:     |  Volumen (24h):